
Tina Stow Tina Stow previously served as Vice President of Communications at PhRMA. Prior to joining PhRMA in 2014, she spent more than a dozen years in corporate and agency communications and public affairs roles. A D.C. transplant via North Carolina and Georgia, Tina likes to travel, make the rounds to D.C.’s new restaurants, dote on her rescue labradoodle (Chloe), and complain about winter.
Recent Posts
Welcome news in two high-profile cancer battles

America’s biopharmaceutical companies are proud to be at the forefront of the battle against cancer, working tirelessly to develop innovative approaches for more effective treatments for patients. ...
Read More
Week in Review: The Latest from PhRMA

340B Spotlight: The latest 340B Spotlight explores contract pharmacy arrangements. Learn more about the history of contract pharmacy arrangements and why a policy change in 2010 led to a dramatic...
Read More
New PhRMA Report: 836 medicines and vaccines in development to treat cancers

Almost all of us have fought – or know someone who is fighting – the ruthless disease author Siddhartha Mukherjee termed, “the emperor of all maladies.” Today, cancers remain the second-leading cause...
Read More
ICYMI – New York Times Editorial Board: Hepatitis C medicines a high value for patients and health care system

In a September 2 editorial, The New York Times Editorial Board concludes that “competitive market forces and hard-nosed bargaining” make “tremendously effective” new hepatitis C medicines not just...
Read More
The drug development and approval process is about much more than the final “okay”

A recent Forbes story not only presents an oddly limited look at the U.S.’s drug development process, it also sends a misleading message to America’s patients and health care professionals. “The FDA...
Read More
ICYMI: Wall Street Journal and Washington Post Say TPP Should Protect Medical Innovation

In case you missed it, The Wall Street Journal and The Washington Post editorialized yesterday on the Trans-Pacific Partnership (TPP) and the importance of reaching a trade deal that protects U.S....
Read More
Fact Check Friday: The Truth about IPR and Biopharmaceutical Patents

Today, we’re pleased to be kicking off our newest Catalyst blog series: Fact Check Friday. We’ll be using this space to separate truth from fiction and set the record straight when the rhetoric...
Read More
Patient Groups, Members of Congress and Other State-Based Stakeholders Agree: Stop the Abuse of Biopharmaceutical Patents

As Congress considers patent legislation known as H.R. 9, the Innovation Act, and S. 1137, the PATENT Act, health care leaders – from patient groups to Members of Congress to trade associations –...
Read More
In Case You Missed It: Progress and Promise in Alzheimer’s Research

PhRMA recently convened a panel of health care experts for a live webcast discussion about the current state of research to treat and care for Alzheimer’s disease. Dr. Bill Chin of PhRMA moderated...
Read More
New PhRMA and Epilepsy Foundation Report: 420 Medicines in Development for Neurological Disorders

It’s hard to imagine, but there are currently more than 50 million Americans – nearly one-sixth of our population – affected by some type of neurological disorder. While some of these are more...
Read More